ClinicalTrials.Veeva

Menu

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Z

Zhengzhou University

Status

Completed

Conditions

COVID-19
Azvudine

Treatments

Drug: Azvudine
Drug: Paxlovid

Study type

Observational

Funder types

Other

Identifiers

NCT06349655
2023-KY-0865-001

Details and patient eligibility

About

To establish a real-world clinical cohort and database of Azvudine in the treatment of SARS-CoV-2 infection, and to provide stable and reliable evidence for the clinical efficacy and safety evaluation of azvudine in the treatment of SARS-CoV-2 infection.

Enrollment

32,864 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age above 18 years old (including the cut-off value), regardless of gender;
  2. Patients diagnosed with 2019-ncov infection according to the diagnostic criteria of the latest edition of the Diagnosis and Treatment Plan for 2019-ncov Pneumonia issued by the Health Commission of China;
  3. Informed consent has been signed.

Exclusion criteria

  1. Known or suspected allergic to the components of Azivudine tablets;
  2. Patients with severe liver, kidney, heart and other organ damage;
  3. Pregnant or lactating women who planned to give birth during or within 6 months after the trial;
  4. Had participated in other clinical trials or were using investigational drugs within 12 weeks before medication;

Trial design

32,864 participants in 3 patient groups

Azvudine
Description:
COVID-19 patients with Azvudine treatment
Treatment:
Drug: Azvudine
Paxlovid
Description:
COVID-19 patients with Paxlovid treatment
Treatment:
Drug: Paxlovid
Control
Description:
COVID-19 Patients who have not been treated with Azvudine or Paxlovid

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems